Claris Lifesciences receives in-principle approval for Propofol in EU

01 Jun 2011 Evaluate

Claris Lifesciences has received an in-principle approval for its block buster drug ‘Propofol’ in the European Union (EU). This will allow the company to process the registration across 25 countries in the EU.

Propofol, a flagship product of Claris, is an anesthetic product which is widely replacing other anesthetic drug, as recovery from Propofol is more repaid and clear when compared to other anesthetic drug. The molecule involves a complex manufacturing technology, and few competitors world wide.

The market size of the Propofol is estimated to be $750 million world wide and in EU is estimated to be about $150 million.

The company has already received 125 approvals in Europe, while another 105 are in the pipeline. Further, it has received 95 approvals for Propofol across different geographies and another 60 registrations are in the pipeline.

Claris Lifesciences reported a drop of 11.27% in net profit of Rs 79.02 crore for the quarter ended December 2010 compared to Rs 89.06 crore in the same quarter last year. Total income for the quarter marginally decreased 0.18% to Rs 626.69 crore compared to Rs 627.79 crore in the same quarter last year.

Peers
Company Name CMP
Redington 216.95
Adani Enterprises 3263.50
Amrapali Industries 15.35
Rashi Peripheral 341.75
Compuage Infocom 3.71
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.